Last update 07 Nov 2024

KYV-101

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Autologous anti-CD19 CAR T cell immunotherapy transduced with lentiviral vector (Kyverna), KYV 101, KYV101
Target
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), T lymphocyte replacements
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US), Regenerative Medicine Advanced Therapy (US), Fast Track (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisPhase 2-01 Jan 2025
Rheumatoid ArthritisPhase 2-01 Nov 2024
Ischiopatellar DysplasiaPhase 2
US
25 Sep 2024
Stiff-Person SyndromePhase 2
US
25 Sep 2024
Multiple Sclerosis, Primary ProgressivePhase 2
US
01 Sep 2024
Multiple Sclerosis, Secondary ProgressivePhase 2
US
01 Sep 2024
Myasthenia GravisPhase 2
US
28 Aug 2024
Myasthenia GravisPhase 2
DE
28 Aug 2024
Scleroderma, DiffusePhase 2
US
06 Aug 2024
Lupus NephritisPhase 2
DE
01 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
41
eqkclusmsk(evmaummuij) = In stiff-person syndrome, two patients treated with KYV-101 have demonstrated improved mobility and/or walking speed and reduced autoantibody titers, including one patient at greater than one year post-infusion. A third patient demonstrated reduced autoantibody titers but does not yet have mobility scores available. In myasthenia gravis, three patients treated with KYV-101 have shown reduced pathogenic anti-AChR antibody titers and sustained disease control, including two patients at more than one year post-infusion and all three at greater than 8 months post-infusion. In multiple sclerosis, five patients treated with KYV-101 who failed prior anti-CD20 medications have shown a significant and unprecedented average reduction in oligoclonal bands in the central nervous system (CNS), a potential surrogate biomarker for reduced disease progression. snxazhfbnn (fvffhvoagi )
Positive
18 Sep 2024
Not Applicable
1
vvkutjatlr(fyndynifki) = gfttmylavu omuyphardc (xysksiealq )
Positive
17 Jun 2024
Not Applicable
1
(lamkuuectn) = zjtkiyuxyg ymvglipdez (lojgvqqpyd )
Positive
15 Nov 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free